We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Evelo Biosciences Inc (EVLO) USD0.001

Sell:$0.0001 Buy:$0.0001 Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.0001
Buy:$0.0001
Change: No change
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.0001
Buy:$0.0001
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.

Contact details

Address:
124 WASHINGTON STREET, SUITE 101
FOXBORO
02035
United States
Telephone:
+1 (617) 5770300
Website:
https://evelobio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EVLO
ISIN:
US2997342025
Market cap:
$1,890
Shares in issue:
18.93 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Craig Jalbert
    President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, Company Secretary, Director
  • Mark Bodmer
    Chief Scientific Officer, President of Research and Development
  • Daniel Char
    General Counsel, Secretary
  • Duncan McHale
    Chief Medical Officer
  • Mark Plinio
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.